Cognition Therapeutics Inc (CGTX)
$1.03
$-0.03
(-2.38%)
As on 04-Sep-2026 13:37EDT
Market cap
$97 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
95,093,746
5 Years Aggregate
CFO
$-44.71 Mln
EBITDA
$-94.46 Mln
Net Profit
$-52.34 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cognition Therapeutics Inc (CGTX)
| -24.1 | 15.0 | -27.8 | -56.8 | -13.1 | -- | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Cognition Therapeutics Inc (CGTX)
| 92.5 | -61.8 | -11.9 | -66.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cognition Therapeutics Inc (CGTX)
|
1.0 | 97.0 | 0.0 | -16.8 | -- | -49.9 | -- | 3.1 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Cognition Therapeutics Inc (CGTX)
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its... lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York. Read more
-
CEO, President & Director
Ms. Lisa Ricciardi
-
CEO, President & Director
Ms. Lisa Ricciardi
-
Headquarters
Purchase, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cognition Therapeutics Inc (CGTX)
What is the current share price of Cognition Therapeutics Inc (CGTX) Today?
The share price of Cognition Therapeutics Inc (CGTX) is $1.03 (NASDAQ) as of 04-Sep-2026 13:37 EDT. Cognition Therapeutics Inc (CGTX) has given a return of -13.06% in the last 3 years.
What is the current PB & PE ratio of Cognition Therapeutics Inc (CGTX)?
Since, TTM earnings of Cognition Therapeutics Inc (CGTX) is negative, P/E ratio is not available.
The P/B ratio of Cognition Therapeutics Inc (CGTX) is 3.08 times as on 28-Aug-2026, a 41 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.11 |
3.50 |
2024 |
-0.96 |
1.74 |
2023 |
-2.21 |
2.33 |
2022 |
80.43 |
1.51 |
2021 |
-11.30 |
2.58 |
What is the 52 Week High and Low of Cognition Therapeutics Inc (CGTX)?
The 52-week high and low of Cognition Therapeutics Inc (CGTX) are Rs 2.67 and Rs 0.55 as of 06-Sep-2026.
What is the market cap of Cognition Therapeutics Inc (CGTX)?
Cognition Therapeutics Inc (CGTX) has a market capitalisation of $ 97 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cognition Therapeutics Inc (CGTX)?
Before investing in Cognition Therapeutics Inc (CGTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.